Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ:HRMY
Want to see HRMY full AI Analyst Report?
HRMY Stock Chart & Stats
$29.99
-$1.07(-3.04%)
At close: 4:00 PM EST
$29.99
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.87
Previous CloseN/A
Volume87.33K
Average Volume (3M)793.93K
Market Cap
$2.04B
Enterprise Value$1.45B
Total Cash (Recent Filing)$640.92M
Total Debt (Recent Filing)$206.51M
Price to Earnings (P/E)13.7
Beta1.05
Next Earnings
Aug 11, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.52
Shares Outstanding57,892,677
10 Day Avg. Volume942,659
30 Day Avg. Volume793,933
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.47
Price to Sales (P/S)2.48
P/FCF Ratio6.18
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue1.61
Enterprise Value/Gross Profit2.10
Enterprise Value/Ebitda6.20
Forecast
1Y Price Target
$49.50Price Target Upside65.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)3.51
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and a large cash balance materially improve financial flexibility. Harmony can fund commercial expansion, defend IP, and pursue BD without near-term financing, supporting sustained investment in growth and R&D through the pipeline build (targeting 2028–2032 revenue).
High Margins And Cash ConversionConsistently very high gross margins and operating cash flow that exceeds net income signal durable earnings quality and pricing power in the specialty rare‑disease channel. Reliable FCF convertibility underpins reinvestment capacity and reduces reliance on external capital over the medium term.
Commercial Traction, Pipeline & IPGrowing sales and low current market penetration (~10–11%) indicate meaningful organic upside for WAKIX. Simultaneously, a diversified late‑stage pipeline and layered IP (settlements plus patents to 2042/2044 filings) create multiple, durable avenues to sustain and expand revenue beyond the base product.
Bears Say
Sales Growth DecelerationGrowth has clearly decelerated from prior multi‑year expansion, reflecting market‑access friction and seasonality. Because WAKIX remains the primary revenue source, meaningful revenue reacceleration depends on broader patient uptake or pipeline approvals, which are mostly not expected to contribute materially until 2027–2028.
Rising COGS And Operating ExpenseHigher royalties tied to the Novitium license and an elevated opex base (including a material upfront license payment) compress margins and temporarily impair cash flow. Even excluding the one‑time fee, step‑up opex and royalty commitments could keep free cash flow recovery muted until scale or price/mix improvements offset them.
Litigation And Competitive RiskPending and newly filed suits extend exclusivity uncertainty into 2027+ and carry appeal risk. Legal outcomes could materially affect generic entry timing or require settlements. Concurrently, advancing orexin agonists raise the risk that the competitive landscape is more crowded when next‑gen products might commercialize, pressuring future market share and pricing.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $25.52 and its highest was $40.87 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $2.04B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 59 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on May 07, 2026. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.695 by -$0.145.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.88.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 57,892,677 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $0.55 in its last earnings report, missing expectations of $0.695. Following the earnings report the stock price went down -4.149%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.50 (65.06% Upside)
$49.50 (65.06% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 142.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.17%
12-Months-Change
Fundamentals
Return on Equity
17.19%
Trailing 12-Months
Asset Growth
20.49%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
HRMY Company Deck
HRMY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company with strong commercial momentum (17% revenue growth, reaffirmed $1.0–1.04B guidance), a well-funded balance sheet ($870.5M cash), advancing pipeline programs with near-term milestones (BP-205, pitolisant GR/HD, EPX-100), and an assertive IP defense strategy. Offsetting these positives were higher COGS and a sizable increase in operating expenses driven largely by a $32M upfront license fee, a decline in GAAP net income, muted cash flow for the quarter, ongoing litigation with timing/appeal uncertainty, and Q1 market access headwinds. On balance, highlights—particularly revenue traction, cash runway, and pipeline progress—outweigh the lowlights but the company faces near-term cost, legal and access execution risks.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$49.50
▲(65.06% Upside)
Technical Analysis
Ownership Overview
1.11% Insiders
20.47% Mutual Funds
17.09% Other Institutional Investors
32.68% Public Companies and Individual Investors